Clinical Trials
1
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
1
100.0%
No approval data available
- FDA released draft guidance on September 25, 2025, for expedited programs supporting regenerative medicine therapies treating serious conditions. - The guidance allows flexible clinical trial designs including adaptive trials, novel endpoints, and real-world evidence for RMAT-designated products. - Recent RMAT designations include Genascence's gene therapy for knee osteoarthritis and VeonGen's VG801 for Stargardt disease. - Manufacturing standards remain stringent despite accelerated timelines, requiring robust comparability data and early CBER engagement.
- The FDA has granted Fast Track designation to GNSC-001, a novel gene therapy for knee osteoarthritis, potentially expediting its development and review. - GNSC-001 is designed to deliver long-term inhibition of interleukin-1 (IL-1) by expressing an optimized form of IL-1 receptor antagonist (IL-1Ra) in the affected knee. - Phase 1 clinical trial data showed that GNSC-001 was well-tolerated, with patients reporting improvements in pain and function scores over a 12-month period. - Osteoarthritis affects millions of Americans, and GNSC-001 represents a potential advancement over current treatments that only provide short-term symptom relief.
